OTC · Biotechnology

Nymox Pharmaceutical Corporation (NYMXF) Stock

$0.01 +20.00% OTC: NYMXF Healthcare

Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207).

Valuation

MetricValue
Price$0.01
Market Cap$1.13M
P/E Ratio-0.25
P/B Ratio-0.17
P/S Ratio0.00
EPS (TTM)$-0.05
52-Week High$0.20
52-Week Low$0.01
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE90.31%
ROA-686.85%
ROCE63.22%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio0.09

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-12.0M$-13.0M$-7.0M$-8.0M$-4.0M
Net Profit$-12.0M$-13.0M$-7.0M$-9.0M$-4.0M
EPS$-0.16$-0.15$-0.07$-0.10$-0.05
Op Margin-234400.0%————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$5.0M$2.0M$2.0M$1.0M$1.0M
Total Liabilities$2.0M$2.0M$2.0M$4.0M$7.0M
Cash$4.0M$1.0M$1.0M$0$0
Borrowings$0$0$0$1.0M$0

Latest News

Nymox's Nymozarfex(TM) Newly Available for Prostate Treatments for Medical Tourists in Collaboration with the Global Alliance of Regenerative Medicine on Roatan Island in the Caribbean ACCESS Newswire · Jun 17, 2026 NYMOX Provides Current Update ACCESS Newswire · Jun 2, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-10.0M$-10.0M$-5.0M$-4.0M$-3.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-2.0M$-3.0M$1.0M$1.0M$0
Free Cash Flow$-10.0M$-10.0M$-5.0M$-4.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.25
FCF Yield-229.27%
Quick Ratio0.09
Interest Coverage-18.95
Return 1Y-85.07%
Return 3Y-98.69%
Return 5Y—

Ownership

Insiders Held45.18%
Institutions Held0.04%
Institutions Float Held0.08%
Institutional HolderSharesReport Date
First Citizens Financial Corporation35,1002026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma. Beyond its drug pipeline, Nymox develops and offers two diagnostic products: NicAlert, which identifies tobacco usage, and TobacAlert, designed to detect exposure to secondhand smoke. The company is also actively engaged in developing treatments for Alzheimer's disease. Nymox Pharmaceutical Corporation was established in 1989 and maintains its headquarters in Nassau, the Bahamas.

Nymox Pharmaceutical Corporation is headquartered in BS.

Nymox Pharmaceutical Corporation (NYMXF) stock trades at $0.01 with a market capitalization of $1.13M. The stock is valued at a price-to-earnings (P/E) ratio of -0.25, price-to-book of -0.17, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $0.20, and currently trades 95.0% below its 52-week high.

On profitability, Nymox Pharmaceutical Corporation generates a return on equity (ROE) of 90.31% — well above the market average, a sign of a high-quality business, return on capital employed of 63.22%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: nymox.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides